Prevention and/or treatment of CNS disorders
US11806350B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 17, 2021 |
| Grant date | Nov 7, 2023 |
| Priority date | — |
| Expiry date | Nov 24, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds are disclosed. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson's disease. The compounds and compositions may also find use in various therapeutic applications including the treatment of cancer and in immuno-oncology.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.